An AI approach to epilepsy drugs
Method speeds up testing of new therapies for hard-to-treat cases
Current testing of less-costly seizure-reducing epilepsy drugs requires days to weeks of video and brain activity monitoring, said neurosurgery professor Ivan Soltesz, PhD. It’s a major bottleneck in drug discovery for the disease, he said.
He and his collaborators are studying a new method that employs machine learning to do the job in just one hour, whether or not a seizure occurs during that time.
In February 2023, they published a paper in Neuron describing the approach’s success in mouse studies. Soltesz was the senior author.
Read more here.
